PT Kalbe Farma Tbk.

Head Ofce KALBE Building Jl. Letjend. Suprapto Kav. 4, Jakarta 10510 Phone (021) 4287-3888; Fax (021) 4287-3678 Website: www.kalbe.co.id Kawasan Industri Delta Silicon Jl. MH. Thamrin Blok A3-I Lippo Cikarang, Bekasi 17550 Phone (021) 8990-7337, 8990-7333 Fax (021) 8990-7360 Pharmaceuticals PMDN

Pharmaceuticals Summary of Financial Statement

(Million Rupiah) 2008 2009 2010

Factory

Business Company Status

Financial Performance: Net income in 2010 increase to IDR 1.286 trillion compared to IDR 929 billion booked in 2009. Brief History: Established in 1966, PT Kalbe Farma Tbk. (the Company or Kalbe) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. Throughout its more than 40-year history, the Company has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise with unrivalled innovation, marketing, branding, distribution, nancial strength and R&D and production expertise to promote its mission to improve health for a better life. The Kalbe Group has an extensive and strong portfolio of brands in the prescription pharmaceuticals, OTC pharmaceuticals, energy drink and nutrition products, complemented with a robust packaging and distribution arm that reaches over 1 million outlets. The Company has succeeded in promoting its brands as the undisputed market leaders not only in Indonesia but also in the international markets, establishing such household names across all healthcare and pharmaceutical segments as Promag, Mixagrip, Woods, Komix, Prenagen and Extra Joss. Also, fostering and expanding alliances with international partners have accelerated Kalbes advances in international markets and sophisticated R&D ventures as well as the latest pharmaceutical and healthcare developments, including stem cell and cancer research. The Groups consolidation in 2005 has further enhanced production, marketing and nancial capabilities, providing greater leverage to widen local and international exposure. Today, Kalbe is the largest publicly-listed pharmaceutical company in Southeast Asia with over US$ 1 billion in market capitalization and revenues of over Rp 7 trillion. Its cashrich position today also provides for unlimited expansion opportunities in the future.
(million rupiah) 2011 2010

Shareholders PT Gira Sole Prima PT Santa Seha Sanadi PT Diptanala Bahana PT Lucasta Murni Cemerlang PT Ladang Ira Panen PT Bina Artha Charisma PT Kalbe Farma Tbk (Buy Back) Public

10.17% 9.62% 9.49% 9.47% 9.22% 8.67% 7.69% 35.67%

Total Assets Current Assets Non-Current Assets Liabilities Shareholders' Equity Net Sales Profit after Taxes ROI (%) ROE (%) In June

7,894,851 5,804,657 2,090,194 2,049,757 5,845,094 4,948,716 692,856 8.78 11.85

6,876,153 5,027,924 1,848,230 1,733,413 4,649,763 4,706,810 601,858 8.75 12.94

428

Indonesian Capital Market Directory 2011

PT Kalbe Farma Tbk.

Board of Commissioners President Commissioner Drs. Johannes Setijono Commissioners Santoso Oen, BA, Yozef Darmawan Angkasa, Ferdinand Aryanto, Farid A. Moeloek, Wahjudi Prakarsa No 1 2 3 4 5 6 7 8 9 10 11 12 13 Type of Listing First Issue Partial Listing Cooperative Company Listing Bonus Shares Right Issue Bonus Shares Dividend Shares Stock Split Stock Split Bonus Shares Stock Split Additional Listing (Merger) Listing Date 1991 1991 1992 1992 1992 1993 1994 1994 1996 1999 2000 2-Jan-04 21-Dec-05

Pharmaceuticals

Board of Directors President Director Bernadette Ruth Irawati Setiady Vice President Director Johanes Berchman Apik Ibrahim Directors Budi Dharma Wireksoatmodjo, Vidjongtius, Ongkie Tedjasurja Number of Employees 9,615 Trading Date 1991 1992 1999 1992 1992 1993 1994 1994 1996 1999 2000 2-Jan-04 21-Dec-05 Number of Shares per Listing 10,000,000 10,000,000 500,000 29,500,000 50,000,000 8,000,000 75,600,000 32,400,000 216,000,000 1,728,000,000 1,900,800,000 4,060,800,000 2,034,414,422 Total Listed Shares 10,000,000 20,000,000 20,500,000 50,000,000 100,000,000 108,000,000 183,600,000 216,000,000 432,000,000 2,160,000,000 4,060,800,000 8,121,600,000 10,156,014,422

Underwriters PT Ing Barings Securities, PT Merincorp Stock Price, Frequency, Trading Days, Number and Value of Shares Traded and Market Capitalization

Stock Price and Traded Chart

Stock Price (Rp) 4,000 3,500 3,000 140 2,500 2,000 1,500 1,000 40 500 Jan-10 Feb-10Mar-10 Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 Feb-11Mar-11 Apr-11 May-11 Jun-11

Million Share 200 180 160

120 100 80 60

20 -

Institute for Economic and Financial Research

429